Protagonist Therapeutics, which is developing peptide-based oral drugs for inflammatory bowel disease, raised $90 million by offering 7.5 million shares at $12, within the range of $11 to $13. The company had originally planned to raise $70 million by offering 5.84 million shares. Insiders had indicated on buying up to $40 million of the IPO. Protagonist Therapeutics plans to list on the Nasdaq under the symbol PTGX. Leerink Partners, Barclays and BMO Capital Markets acted as lead managers on the deal.
Blogger Comment
Facebook Comment